

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 10, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Proteostasis Therapeutics, Inc.

File No. 333-208735 - CF#32651

Proteostasis Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on December 23, 2015, as amended.

Based on representations by Proteostasis Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through June 18, 2025
Exhibit 10.2	through June 18, 2018
Exhibit 10.3	through June 18, 2018
Exhibit 10.4	through June 18, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary